Adagrasiib Drug Encyclopedia

Adagrasib is a targeted therapy drug that is a KRAS G12C inhibitor. It is used to treat advanced or metastatic non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, as well as other solid tumors with the same mutation.

KRAS G12Cmutation is a common oncogenic mutation, which leads to abnormal activation of theRAS signaling pathway, thereby promoting the growth, proliferation and metastasis of tumor cells. By specifically binding to and inhibiting KRAS G12C mutants, adagrasib interferes with this lethal signaling pathway, thereby inhibiting tumor growth and spread.

Adagrasiib is administered orally at a dose of 600mg twice daily, for a total of 1200mg per day. This usage makes it more convenient in treatment and provides better patient compliance.

Clinical trials have shown that adagrasib exhibits significant anti-tumor activity in some patients with advanced cancer. Although further studies are still needed to determine its long-term efficacy and safety, adagrasib offers a new treatment option for those with the KRAS G12C mutation, particularly those who previously lacked effective treatments.

However, adagrasib may also cause a range of adverse reactions, including fatigue, digestive problems (such as nausea, vomiting, diarrhea), skin reactions, muscle spasms, high blood pressure, etc. Therefore, when using adagrasib, physicians need to carefully weigh the potential benefits and risks and monitor closely with patients.

Overall, adagrasib represents a cutting-edge cancer treatment approach that offers new hope for those suffering fromKRAS G12Cmutations. With further research and clinical practice, it is believed that it will play an increasingly important role in the field of cancer treatment.